Header Logo

Connection

SRDAN VERSTOVSEK to Thalidomide

Back to Details
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Thalidomide.
SRDAN VERSTOVSEK
Connection Strength
2.999
Thalidomide
  1. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res. 2016 09; 48:1-5.
    View in: PubMed
    Score: 0.420
  2. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer Res. 2015 Oct; 35(10):5219-23.
    View in: PubMed
    Score: 0.399
  3. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9.
    View in: PubMed
    Score: 0.367
  4. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4.
    View in: PubMed
    Score: 0.343
  5. Breakthroughs in myeloproliferative neoplasms. Hematology. 2012 Apr; 17 Suppl 1:S55-8.
    View in: PubMed
    Score: 0.313
  6. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902.
    View in: PubMed
    Score: 0.295
  7. Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis. Leuk Res. 2008 May; 32(5):821-2.
    View in: PubMed
    Score: 0.229
  8. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961.
    View in: PubMed
    Score: 0.110
  9. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63.
    View in: PubMed
    Score: 0.098
  10. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 01; 36(4):560-6.
    View in: PubMed
    Score: 0.090
  11. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5.
    View in: PubMed
    Score: 0.083
  12. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.066
  13. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009 Sep 20; 27(27):4563-9.
    View in: PubMed
    Score: 0.065
  14. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 01; 106(9):1974-84.
    View in: PubMed
    Score: 0.052
  15. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64.
    View in: PubMed
    Score: 0.052
  16. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.